ONWARD Medical Achieves Key Milestones in Q3 2025

ONWARD Medical reported a significant uptick in the adoption of its ARC-EX® System, selling 40 units in Q3 2025. This development reflects growing commercial traction in the US. Regulatory milestones were also achieved, with the FDA approving an IDE for the ARC-IM® System, paving the way for the Empower BP global pivotal study. Additionally, the ARC-EX System received CE Mark certification for European markets and FDA clearance for home use in the US.

Scientific advancements were highlighted with key publications in renowned journals like Nature and Nature Medicine, supporting ONWARD's neuromodulation technologies. Financially, the company generated EUR 1.7 million in Q3 revenue and secured over EUR 50 million in equity, extending its cash runway into Q1 2027. With these accomplishments, ONWARD is well-positioned for continued growth in 2026.